These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34235560)

  • 21. ZILVERPASS Study: ZILVER PTX Stent vs. Bypass Surgery in Femoropopliteal Lesions, 3 year results and economic analysis.
    Bosiers M; DE Donato G; Torsello G; Galvagni Silveira P; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Tessarek J; Giaquinta A; van den Eynde W; Verbist J; Wahl-Gravsen J; Bosiers MJ
    J Cardiovasc Surg (Torino); 2023 Aug; 64(4):413-421. PubMed ID: 37162238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results.
    Bosiers MJ; De Donato G; Torsello G; Silveira PG; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Eckstein HH; Teβarek J; Giaquinta A; van den Eynde W; Verbist J; Callaert J; Deloose K; Bosiers M
    Cardiovasc Intervent Radiol; 2023 Oct; 46(10):1348-1358. PubMed ID: 37670198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1832-1838. PubMed ID: 28948322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy analysis following polymer coated drug eluting stent and bare metal stent deployment for femoropopliteal arterial disease.
    Shehada Y; Bisdas T; Argyriou A; Torsello G; Tsilimparis N; Beropoulis E; Stavroulakis K
    Vascular; 2024 Feb; 32(1):102-109. PubMed ID: 36070428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
    Ichihashi S; Shibata T; Fujimura N; Nagatomi S; Yamamoto H; Kyuragi R; Adachi A; Iwakoshi S; Bolstad F; Saeki K; Obayashi K; Kichikawa K
    J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
    [No Abstract]   [Full Text] [Related]  

  • 26. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
    Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
    J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective.
    Altaf N; Ariyaratne TV; Peacock A; Deltetto I; El-Hoss J; Thomas S; Taylor C; Mwipatayi BP
    Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1375-1383. PubMed ID: 34155526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
    Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Femoropopliteal Artery Disease with Polymer-Coated Drug-Eluting Stent: 5-Year Results of a Prospective, Non-Randomized Study Including the Halo Phenomenon.
    Torsello GF; Stavroulakis K; Bisdas T; Cardona Y; Wichmann K; Torsello GB
    Cardiovasc Intervent Radiol; 2024 Feb; 47(2):177-185. PubMed ID: 38228879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.
    Bosiers M; Peeters P; Tessarek J; Deloose K; Strickler S;
    J Cardiovasc Surg (Torino); 2013 Feb; 54(1):115-22. PubMed ID: 23296421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels-Results from the Zilver PTX Japan Post-Market Surveillance Study.
    Cipollari S; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    J Vasc Interv Radiol; 2018 Jan; 29(1):9-17.e1. PubMed ID: 29122449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-Term Results of Eluvia™ Paclitaxel-Eluting Stent in External Iliac and Femoropopliteal Lesions.
    Elens M; Verhelst R; Possoz J; Mastrobuoni S; Lacroix V; Astarci P
    Surg Technol Int; 2017 Nov; 31():162-167. PubMed ID: 29121693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
    Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
    J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
    [No Abstract]   [Full Text] [Related]  

  • 35. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
    Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
    J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
    Fujihara M; Utsunomiya M; Higashimori A; Yokoi Y; Nakamura M
    Heart Vessels; 2016 Feb; 31(2):152-7. PubMed ID: 25351136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia.
    Kum S; Ipema J; Huizing E; Tan YK; Lim D; Lok IY; Hazenberg CE; Ünlü Ç
    Vasc Med; 2021 Jun; 26(3):267-272. PubMed ID: 33733963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
    Stern JR; Tran K; Chandra V; Harris EJ; Lee JT
    Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.
    Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Snyder SA; O'Leary EE; Tepe G; Scheinert D; Zeller T;
    J Am Coll Cardiol; 2013 Jun; 61(24):2417-2427. PubMed ID: 23583245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.